Magenta Therapeutics

Magenta, Beam partner to explore use of antibody-based conditioning drug for gene therapies
Magenta, Beam partner to explore use of antibody-based conditioning drug for gene therapies
MedCity News
Magenta Therapeutics
Beam Therapeutics
MGTA-117
gene therapy
sickle cell disease
beta thalassemia
Flag link:
The Week Ahead In Biotech: ASH 2019 Gets Underway, Biogen's Aducanumab Data And More
The Week Ahead In Biotech: ASH 2019 Gets Underway, Biogen's Aducanumab Data And More
Yahoo/Benzinga
ASH2019
Roche
Bristol-Myers Squibb
Acadia Pharmaceuticals
Biogen
Cassava Sciences
Alector
GW Pharma
Magenta Therapeutics
Fortress Biotech
Mustang Bio
Bluebird Bio
Flag link:
2 Small-Cap Biotechs That Soared Last Week
2 Small-Cap Biotechs That Soared Last Week
Motley Fool
Magenta Therapeutics
Molecular Templates
gene therapy
CAR-T
cancer
Flag link:
Magenta Therapeutics presents updated Phase 2 clinical data on MGTA-456 cell therapy
Magenta Therapeutics presents updated Phase 2 clinical data on MGTA-456 cell therapy
Pharmaceutical Business Review
Magenta Therapeutics
cell therapy
clinical trials
MGTA-456
inherited metabolic disorders
metabolic disorders
Flag link:
Magenta stem cell transplant drug seems to work, but is it safe?
Magenta stem cell transplant drug seems to work, but is it safe?
Fierce Biotech
Magenta Therapeutics
MGTA-456
clinical trials
stem cells
Flag link:
Bio IPO Madness: Six Biotech Startups Raise $568M in 24 Hours
Bio IPO Madness: Six Biotech Startups Raise $568M in 24 Hours
Xconomy
biotech
IPOs
Eidos Therapeutics
Avrobio
XERIS
Aptinyx
Kezar Life Sciences
Magenta Therapeutics
Flag link:
Three Biotechs Announced IPOs Friday
Three Biotechs Announced IPOs Friday
BioSpace
IPOs
Autolus
Magenta Therapeutics
MeiraGTx
Flag link:
Magenta Therapeutics Launches $100 Million IPO
Magenta Therapeutics Launches $100 Million IPO
CP Wire
Magenta Therapeutics
IPOs
Flag link:
Magenta Therapeutics Launches $100 Million IPO
Magenta Therapeutics
Flag link:
Five months, $98.5M and a PhII drug from Novartis later, Magenta Therapeutics is flooring it
Five months, $98.5M and a PhII drug from Novartis later, Magenta Therapeutics is flooring it
Endpoints
Magenta Therapeutics
Novartis
stem cells
HSC835
Flag link: